

PALTOWN Teams up With Guardant Health

Campaign to Promote Complete Biomarker Testing for Advanced CRC Patients

CROWNSVILLE, MD, UNITED STATES,
March 24, 2021 /EINPresswire.com/ --
FOR IMMEDIATE RELEASE

PALTOWN TEAMS UP WITH [GUARDANT HEALTH](#) TO RAISE AWARENESS OF COMPLETE BIOMARKER TESTING
Comprehensive Testing May Inform Treatment and Improve Outcomes for Advanced CRC Patients
PALTOWN Development Foundation today announced it will be joining forces with Guardant Health to raise awareness of the importance of complete biomarker testing, which may help more than 60% of advanced [colorectal cancer](#) patients identify more effective treatment.



PALTOWN Development Foundation is a 501(c)3 dedicated to addressing information needs and social isolation through training, technology, and purpose-driven community leadership.

Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, is teaming up with patient advocacy groups like PALTOWN and its flagship CRC peer to peer community COLONTOWN, of 5,700 patients and caregivers, to expand the Clear Your View initiative. The campaign, now in its second year, is expanding its focus to colorectal cancer, the second leading cause of cancer death and the third most commonly diagnosed cancer in the U.S. Clear Your View encourages oncologists to “stop, test, and wait” for complete biomarker testing results before starting first-line treatment. Complete biomarker testing plays an important role in guiding initial treatment decisions for newly diagnosed advanced colorectal cancer (CRC) patients.

“We are excited to help our advanced patients learn more about personalized biomarker testing that may guide treatment decisions and improve outcomes,” said Susan Wysoki, Interim Executive Director of PALTOWN Development Foundation. “We are proud to stand with other

CRC advocacy groups to support these potentially lifesaving treatments.”

“Incredible progress has been made in personalized treatments for advanced colorectal cancer, including not only medicines in clinical trials, but available FDA-approved medicines, yet too many patients are missing out on these potentially life-changing treatments due to suboptimal biomarker testing rates,” said Helmy Eltoukhy, Guardant Health CEO. “Additionally, many patients are being treated with potentially less efficacious treatments. Through the expansion of the Clear Your View initiative, we join the colorectal cancer community in urging wider adoption of complete biomarker testing to help ensure the best treatments for all patients suffering from advanced cancer.”

The Clear Your View campaign is being delivered to oncologists nationwide. To learn more about the campaign and the importance of complete biomarker testing for all advanced NSCLC and CRC patients, visit: clearyourview.org.

About PALTOWN

PALTOWN currently supports over 5600 patients and caregivers in its exclusive online community COLONTOWN, a unique model of patient-led empowerment, with over 120 private “neighborhoods” for patients and caregivers to gain the emotional and psychosocial support they need, as well as the latest science-based data to inform their care and treatment. For more information, visit: paltown.org.

About Guardant Health

Guardant Health is a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary blood tests, vast data sets and advanced analytics. The Guardant Health oncology platform leverages capabilities to drive commercial adoption, improve patient clinical outcomes and lower healthcare costs across all stages of the cancer care continuum. Guardant Health has commercially launched liquid biopsy-based Guardant360®, Guardant360 CDx, and GuardantOMNI® tests for advanced stage cancer patients, and Guardant Reveal™ for early-stage cancer patients. These tests fuel development of its LUNAR screening program, which aims to address the needs of asymptomatic individuals eligible for cancer screening and individuals at a higher risk for developing cancer with early detection.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of federal securities laws, including statements regarding the potential scope, impact or benefit of Guardant Health liquid biopsies and the Clear Your View campaign, which involve risks and uncertainties that could cause the actual results to differ materially from the anticipated results and expectations expressed in these forward-looking statements. These statements are based on current expectations, forecasts and assumptions, and actual outcomes and results could differ materially from these statements due to a number of factors.

These and additional risks and uncertainties that could affect Guardant Health's financial and operating results and cause actual results to differ materially from those indicated by the forward-looking statements made in this press release include those discussed under the captions "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operation" and elsewhere in its Annual Report on Form 10-K for the year ended December 31, 2020, in its other reports filed with the Securities and Exchange Commission, including when filed, its Quarterly Report on Form 10-K for the period ended March 31, 2021. The forward-looking statements in this press release are based on information available to Guardant Health as of the date hereof, and Guardant Health disclaims any obligation to update any forward-looking statements provided to reflect any change in its expectations or any change in events, conditions, or circumstances on which any such statement is based, except as required by law. These forward-looking statements should not be relied upon as representing Guardant Health's views as of any date subsequent to the date of this press release.

Media Contact:

Susan Wysoki
(804 221-7084
swysoki@paltown.org

Anna Czene
press@guardanthealth.com

Courtney Carroll
courtney.carroll@uncappedcommunications.com

Nancy Seybold
PALTOWN Development Foundation
+1 4108813160
[email us here](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/537458280>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2021 IPD Group, Inc. All Right Reserved.